Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 9, 2017

View Archived Issues

BridgeBio Pharma outlines novel approach in genetic diseases

First subject enrolled in phase IIa study of Therapix Biosciences' THX-TS01

Orion presents Bdr4 inhibitors

Evoke Pharma offers additional data from phase III study of Gimoti

Eisai expands development and marketing rights to Belviq

APT Therapeutics and AstraZeneca enter agreement regarding APT-102

Cerveau finalizes license agreement with Merck & Co. for tau imaging agent

Acucela's emixustat hydrochloride granted orphan drug status in U.S. for Stargardt disease

Genocea Biosciences reports interim results from phase IIb trial of GEN-003

FDA gives orphan drug designation to PTC Therapeutics' RG-7916 for SMA

Argenx initiates phase II study of ARGX-113 for myasthenia gravis

Alexion Pharmaceuticals' ALXN-1210 awarded FDA orphan status for PNH

Ipsen agrees to acquire global oncology assets from Merrimack Pharmaceuticals

PaxVax, NIH and DoD form chikungunya vaccine partnership

FDA conditionally accepts Dsuvia as brand name for AcelRx's ARX-04

Lilly patents somatostatin sst5 receptor antagonists

Astex Pharmaceuticals and GSK describe NRF2 regulators

TGR5 modulators described in Intercept/Servier patent

Corsair Pharma reports prostacyclin analogues for PAH

Hanlin Scientific patents agents for cancer and amyloidosis

Phase III trial of Seciera for dry eye disease meets endpoints

FDA accepts for review BLA for LFB's eptacog beta for hemophilia

Aridis Pharmaceuticals' AR-301 shows promising results in phase I/IIa study

AiCuris begins clinical development of AIC-4998

CalciMedica commences phase I studies of CM-4620

FDA grants fast track status to FCX-007 from Fibrocell Science

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...